Revista Cultura Científica - web logo
Submit Your Research
  • Research Article

Effectiveness of 1% Topical Spironolactone in the Management of Androgenetic Alopecia

Muheera Javaid1, Tehreem Alam Buzdar1, Sumera Hanif1, Iram Kausar1, Ayesha Arshad Chattha1, Meshaal Azhar1, Rania Mubarik1, Haroon Nabi1
1Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
DOI: https://doi.org/10.70517/revcc2624172
Published: 15/10/2026
: Muheera Javaid, Tehreem Alam Buzdar, Sumera Hanif, Iram Kausar, Ayesha Arshad Chattha, Meshaal Azhar, Rania Mubarik, Haroon Nabi. Effectiveness of 1% Topical Spironolactone in the Management of Androgenetic Alopecia. Revista Cultura Científica, 2026 Issue 24. pg. 2093-2103.

Abstract

Androgenetic alopecia (AGA) is a common progressive, nonscarring form of hair loss associated with follicular miniaturization and considerable psychosocial burden. Topical spironolactone is an investigational antiandrogenic approach, but clinical evidence for the 1% formulation remains limited. This study aimed to describe changes in trichoscopic hair-count measures and reported tolerability after 16 weeks of once-daily application of 1% topical spironolactone in patients with AGA. This single-centre descriptive case series included 60 adults aged 18–55 years with clinically diagnosed AGA who attended the Dermatology outpatient department at Lahore Medical and Dental College, Ghurki Trust Teaching Hospital, Lahore, between March and July 2026. All participants applied 1% topical spironolactone once daily to the affected scalp areas for 16 weeks. Trichoscopic findings were recorded at baseline and at week 16. The mean age was 32.12 ± 8.30 years, and 33 participants (55.0%) were male. Mean thin terminal-hair counts increased from 12.73 ± 3.24 to 15.63 ± 5.49, thick terminal-hair counts increased from 17.55 ± 6.88 to 22.78 ± 13.47, total terminal-hair counts increased from 30.28 ± 8.79 to 39.15 ± 17.58, and total hair counts increased from 41.95 ± 11.40 to 48.33 ± 17.42. Mean vellus-hair counts decreased from 11.68 ± 4.14 to 9.18 ± 3.50. The manuscript reports p < 0.001 for these comparisons, although the paired statistical test outputs were unavailable for independent verification. Overall, 42 participants (70.0%) were classified as having an effective treatment response, although the original response criterion requires further clarification. No adverse effects were reported by 50 participants (83.3%), while pruritus was reported by six participants (10.0%) and scalp dryness or peeling by four participants (6.7%). These findings indicate that 16 weeks of treatment with 1% topical spironolactone was associated with favorable within-participant changes in trichoscopic hair-count measures and generally acceptable local tolerability. However, given the absence of a control group and unresolved discrepancies among certain tabulated measurements, the findings should be considered preliminary and cannot establish comparative treatment efficacy or systemic safety.

Keywords: androgenetic alopecia, topical spironolactone, trichoscopy, hair count, terminal hair, vellus hair, observational study

Abstract

Androgenetic alopecia (AGA) is a common progressive, nonscarring form of hair loss associated with follicular miniaturization and considerable psychosocial burden. Topical spironolactone is an investigational antiandrogenic approach, but clinical evidence for the 1% formulation remains limited. This study aimed to describe changes in trichoscopic hair-count measures and reported tolerability after 16 weeks of once-daily application of 1% topical spironolactone in patients with AGA. This single-centre descriptive case series included 60 adults aged 18–55 years with clinically diagnosed AGA who attended the Dermatology outpatient department at Lahore Medical and Dental College, Ghurki Trust Teaching Hospital, Lahore, between March and July 2026. All participants applied 1% topical spironolactone once daily to the affected scalp areas for 16 weeks. Trichoscopic findings were recorded at baseline and at week 16. The mean age was 32.12 ± 8.30 years, and 33 participants (55.0%) were male. Mean thin terminal-hair counts increased from 12.73 ± 3.24 to 15.63 ± 5.49, thick terminal-hair counts increased from 17.55 ± 6.88 to 22.78 ± 13.47, total terminal-hair counts increased from 30.28 ± 8.79 to 39.15 ± 17.58, and total hair counts increased from 41.95 ± 11.40 to 48.33 ± 17.42. Mean vellus-hair counts decreased from 11.68 ± 4.14 to 9.18 ± 3.50. The manuscript reports p < 0.001 for these comparisons, although the paired statistical test outputs were unavailable for independent verification. Overall, 42 participants (70.0%) were classified as having an effective treatment response, although the original response criterion requires further clarification. No adverse effects were reported by 50 participants (83.3%), while pruritus was reported by six participants (10.0%) and scalp dryness or peeling by four participants (6.7%). These findings indicate that 16 weeks of treatment with 1% topical spironolactone was associated with favorable within-participant changes in trichoscopic hair-count measures and generally acceptable local tolerability. However, given the absence of a control group and unresolved discrepancies among certain tabulated measurements, the findings should be considered preliminary and cannot establish comparative treatment efficacy or systemic safety.

Keywords: androgenetic alopecia, topical spironolactone, trichoscopy, hair count, terminal hair, vellus hair, observational study

References

  1. Ntshingila, Sincengile, et al. “Androgenetic Alopecia: An Update.” JAAD International, vol. 13, 2023, pp. 150–58. https://doi.org/10.1016/j.jdin.2023.07.005.

  2. Wang, Chaofan, et al. “The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review.” Clinical, Cosmetic and Investigational Dermatology, vol. 16, 2023, pp. 603–12. https://doi.org/10.2147/CCID.S398950.

  3. Cortez, Gabriel Lazzeri, et al. “Male Androgenetic Alopecia.” Anais Brasileiros de Dermatologia, vol. 100, no. 2, 2025, pp. 308–21. https://doi.org/10.1016/j.abd.2024.08.004.

  4. Vila-Vecilla, Laura, et al. “Genomic Markers and Personalized Medicine in Androgenetic Alopecia: A Comprehensive Review.” Cosmetics, vol. 11, no. 5, 2024, article 148. https://doi.org/10.3390/cosmetics11050148.

  5. Nestor, Mark S., et al. “Treatment Options for Androgenetic Alopecia: Efficacy, Side Effects, Compliance, Financial Considerations, and Ethics.” Journal of Cosmetic Dermatology, vol. 20, no. 12, 2021, pp. 3759–81. https://doi.org/10.1111/jocd.14537.

  6. Alessandrini, Aurora, et al. “Androgenetic Alopecia in Women and Men: Italian Guidelines Adapted from European Dermatology Forum/European Academy of Dermatology and Venereology Guidelines.” Giornale Italiano di Dermatologia e Venereologia, vol. 155, no. 5, 2020, pp. 622–31. https://doi.org/10.23736/S0392-0488.19.06399-5.

  7. Kasumagic-Halilovic, Emina. “Trichoscopic Findings in Androgenetic Alopecia.” Medical Archives, vol. 75, no. 2, 2021, pp. 109–11. https://doi.org/10.5455/medarh.2021.75.109-111.

  8. Varothai, Supenya, and Wilma F. Bergfeld. “Androgenetic Alopecia: An Evidence-Based Treatment Update.” American Journal of Clinical Dermatology, vol. 15, no. 3, 2014, pp. 217–30. https://doi.org/10.1007/s40257-014-0077-5.

  9. Shaw, James C. “Antiandrogen Therapy in Dermatology.” International Journal of Dermatology, vol. 35, no. 11, 1996, pp. 770–78. https://doi.org/10.1111/j.1365-4362.1996.tb02970.x.

  10. Burns, Laura J., et al. “Spironolactone for Treatment of Female Pattern Hair Loss.” Journal of the American Academy of Dermatology, vol. 83, no. 1, 2020, pp. 276–78. https://doi.org/10.1016/j.jaad.2020.03.087.

  11. Kelidari, Hamid Reza, et al. “Spironolactone Loaded Nanostructured Lipid Carrier Gel for Effective Treatment of Mild and Moderate Acne Vulgaris: A Randomized, Double-Blind, Prospective Trial.” Colloids and Surfaces B: Biointerfaces, vol. 146, 2016, pp. 47–53. https://doi.org/10.1016/j.colsurfb.2016.05.042.

  12. Yousef, Ayman E., et al. “Topical Finasteride versus Topical Spironolactone in the Treatment of Androgenetic Alopecia.” The Medical Journal of Cairo University, vol. 88, no. 3, 2020, pp. 1017–22. https://doi.org/10.21608/mjcu.2020.110836.

  13. Kaiser, Michael, et al. “Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs.” Clinical, Cosmetic and Investigational Dermatology, vol. 16, 2023, pp. 1387–1406. https://doi.org/10.2147/CCID.S385861.

  14. Hussein, Sherief Mahdy, et al. “Assessment of the Efficacy of Topical Antiandrogen; Spironolactone in Patients with Androgenetic Alopecia by Dermoscopy.” Journal of Pakistan Association of Dermatologists, vol. 32, no. 3, 2022, pp. 493–501. https://doi.org/10.66344/jpad.v32i3.1976.

  15. Ammar, Amr M., et al. “Dermoscopic Evaluation of the Efficacy of Combination of Topical Spironolactone 5% and Minoxidil 5% Solutions in the Treatment of Androgenetic Alopecia: A Cross Sectional-Comparative Study.” Journal of Cosmetic Dermatology, vol. 21, no. 11, 2022, pp. 5790–99. https://doi.org/10.1111/jocd.15328.

  16. Abdel-Raouf, Hamza, et al. “A Novel Topical Combination of Minoxidil and Spironolactone for Androgenetic Alopecia: Clinical, Histopathological, and Physicochemical Study.” Dermatologic Therapy, vol. 34, no. 1, 2021, article e14678. https://doi.org/10.1111/dth.14678.

  17. Hassan, Ghada Fawzy Rezk, et al. “Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: A Comparative, Clinical, and Trichoscopic Study.” International Journal of Trichology, vol. 17, no. 1, 2025, pp. 42–50. https://doi.org/10.4103/ijt.ijt_118_23.

  18. Sinclair, Rodney, et al. “Treatment of Female Pattern Hair Loss with Oral Antiandrogens.” British Journal of Dermatology, vol. 152, no. 3, 2005, pp. 466–73. https://doi.org/10.1111/j.1365-2133.2005.06218.x.

Muheera Javaid
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
muheera_javaid@hotmail.com
Tehreem Alam Buzdar
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
Sumera Hanif
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
Iram Kausar
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
Ayesha Arshad Chattha
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
Meshaal Azhar
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
Rania Mubarik
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan
Haroon Nabi
Department of Dermatology, Lahore Medical and Dental College, Ghurki Trust and Teaching Hospital, Lahore, Punjab, Pakistan

How to cite:

Muheera Javaid, Tehreem Alam Buzdar, Sumera Hanif, Iram Kausar, Ayesha Arshad Chattha, Meshaal Azhar, Rania Mubarik, Haroon Nabi. Effectiveness of 1% Topical Spironolactone in the Management of Androgenetic Alopecia. Revista Cultura Científica, 2026 Issue 24. pg. 2093-2103.

Publication History

  • Received: 26/06/2026
  • Accepted: 08/10/2026
  • Published: 15/10/2026
Copyright © 2026, Muheera Javaid, Tehreem Alam Buzdar, Sumera Hanif, Iram Kausar, Ayesha Arshad Chattha, Meshaal Azhar, Rania Mubarik, Haroon Nabi. Published by Revista Cultura Científica. This article is published as open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) license (http://creativecommons.org/licenses/by/4.0/).

Browse Advance Search